达沙替尼治疗伊马替尼耐药的慢性髓细胞白血病急变期临床分析

钟丽红, 杜新, 丘创华, 等. 达沙替尼治疗伊马替尼耐药的慢性髓细胞白血病急变期临床分析[J]. 临床血液学杂志, 2016, 29(11): 883-886. doi: 10.13201/j.issn.1004-2806.2016.11.008
引用本文: 钟丽红, 杜新, 丘创华, 等. 达沙替尼治疗伊马替尼耐药的慢性髓细胞白血病急变期临床分析[J]. 临床血液学杂志, 2016, 29(11): 883-886. doi: 10.13201/j.issn.1004-2806.2016.11.008
ZHONG Lihong, DU Xin, QIU Chuanghua, et al. Clinical effect of dasatinib in treatment of imatinib-resistant chronic myeloid leukemia blast crisis[J]. J Clin Hematol, 2016, 29(11): 883-886. doi: 10.13201/j.issn.1004-2806.2016.11.008
Citation: ZHONG Lihong, DU Xin, QIU Chuanghua, et al. Clinical effect of dasatinib in treatment of imatinib-resistant chronic myeloid leukemia blast crisis[J]. J Clin Hematol, 2016, 29(11): 883-886. doi: 10.13201/j.issn.1004-2806.2016.11.008

达沙替尼治疗伊马替尼耐药的慢性髓细胞白血病急变期临床分析

详细信息
    通讯作者: 杜新,E-mail:duxingz@medmail.com.cn
  • 中图分类号: R733.72

Clinical effect of dasatinib in treatment of imatinib-resistant chronic myeloid leukemia blast crisis

More Information
  • 目的:评价达沙替尼治疗伊马替尼耐药的BCR-ABL阳性慢性髓细胞白血病急变期(CML-BC)的疗效和安全性。方法:对7例伊马替尼耐药的CML-BC患者,给予达沙替尼100 mg/d口服治疗,观察达沙替尼对CML患者的血液学、遗传学及分子生物学反应,并监测不良反应,评估疗效和耐受情况。结果:7例伊马替尼耐药的BCR-ABL阳性CML-BC患者服用达沙替尼治疗后均获得完全血液学缓解,4例达到完全细胞遗传学缓解,1例达到完全分子学反应。4例达沙替尼治疗后检测到突变,4例死亡。2例出现3~4级中性粒细胞减少和3~4级血小板减少。结论:达沙替尼治疗伊马替尼耐药的BCR-ABL阳性CML-BC患者起效迅速,可获得完全血液学及细胞遗传学缓解,甚至获得完全分子生物学缓解,但维持时间短,容易再次出现疾病进展。达沙替尼治疗后可出现新的ABL激酶区突变,导致患者对达沙替尼耐药。
  • 加载中
  • [1]

    Pui CH,Evans WE.Treatment of acute lymphoblastic leukemia[J].N Engl J Med,2006,354:166-178.

    [2]

    Marin D,Bazeos A,Mahon FX,et al.Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieving complete cytogenetic responses on imatinib[J].J Clin Oncol,2010,28:2381-2388.

    [3]

    McCormack PL,Keam SJ.Dasatinib:a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome positive acute lymphoblastic leukaemia[J].Drugs,2011,71:1771-1795.

    [4]

    Porkka K,Koskenvesa P,Lundan T,et al.Dsatinib crosses the lood-brain barrier and is an efficient therapy for central nervous system Philadelpphia chromosome-positive leukemia[J].Blood,2008,112:1005-1012.

    [5]

    Johansson B,Fioretos T,Mitelman F.Cytogenetic and molecular genetic evolution of chronic myeloid leukemia[J].Acta Haematol,2002,107:76-94.

    [6]

    Muvarak N,Nagaria P,Rassool FV.Genomic instability in chronic myeloid leukemia:targets for therapy[J].Curr Hematol Malig Rep,2012,7:94-102.

    [7]

    Skorski T.Genetic mechanisms of chronic myeloid leukemia blastic transformation[J].Curr Hematol Malig Rep,2012,7:87-93.

    [8]

    Soverini S,De Benedittis C,Papayannidis C,et al.Drug resistance and BCR-ABL kinase domain mutations in philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era[J].Cancer,2014,120:1002-1009.

    [9]

    Razga F,Jurcek T,Zackova D,et al.Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations[J].Mol Diagn Ther,2014,16:251-259.

    [10]

    McCormack PL,Keam SJ.Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia[J].Bio Drugs,2012,26:61-64.

    [11]

    Latif AL,McQuaker G,Parker A,et al.Allogeneic stem cell transplantation for chronic myeloid leukaemia is safe and effective in high risk patients following second generation tyrosine kinase inhibitors:a single centre's experience[J].Leuk Res Rep,2013,2:47-50.

  • 加载中
计量
  • 文章访问数:  289
  • PDF下载数:  116
  • 施引文献:  0
出版历程
收稿日期:  2015-10-14

目录